Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Valuing health States for use in cost-effectiveness analysis.

Literature DB >> 18767897

Valuing health States for use in cost-effectiveness analysis.

Abstract

This article reviews the general issues in valuing health states for use in cost-effectiveness analysis and the specific issues considered by the National Institute for Health and Clinical Excellence (NICE) in its recent review of the methods of technology appraisal. The general issues are how to describe health, how to value health and who should provide the values for health. The specific issues considered by NICE included whether and what should be the reference-case instrument, what to do when there are no data using the reference-case measure, what to do when the reference-case measure is not suitable and how to judge when it is not suitable, how to review and synthesize data, and how to incorporate health-state utility values into cost-effectiveness models.

Mesh：

Year: 2008 PMID： 18767897 DOI： 10.2165/00019053-200826090-00007

Source DB: PubMed Journal: Pharmacoeconomics ISSN： 1170-7690 Impact factor: 4.981

34 in total

Review 1. Theory versus practice: a review of 'willingness-to-pay' in health and health care.

Authors: J A Olsen; R D Smith
Journal: Health Econ Date: 2001-01 Impact factor: 3.046

2. The estimation of a preference-based measure of health from the SF-36.

Authors: John Brazier; Jennifer Roberts; Mark Deverill
Journal: J Health Econ Date: 2002-03 Impact factor: 3.883

Review 3. A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety.

Authors: E Kaltenthaler; P Shackley; K Stevens; C Beverley; G Parry; J Chilcott
Journal: Health Technol Assess Date: 2002 Impact factor: 4.014

Review 4. EuroQol: the current state of play.

Authors: R Brooks
Journal: Health Policy Date: 1996-07 Impact factor: 2.980

5. US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

Authors: James W Shaw; Jeffrey A Johnson; Stephen Joel Coons
Journal: Med Care Date: 2005-03 Impact factor: 2.983

6. Working with children to develop dimensions for a preference-based, generic, pediatric, health-related quality-of-life measure.

Authors: Katherine J Stevens
Journal: Qual Health Res Date: 2010-01-06

7. Mapping visual analogue scale health state valuations onto standard gamble and time trade-off values.

Authors: P Dolan; M Sutton
Journal: Soc Sci Med Date: 1997-05 Impact factor: 4.634

8. Does "process utility" exist? A case study of willingness to pay for laparoscopic cholecystectomy.

Authors: C Donaldson; P Shackley
Journal: Soc Sci Med Date: 1997-03 Impact factor: 4.634

9. Empirically defined health states for depression from the SF-12.

Authors: C A Sugar; R Sturm; T T Lee; C D Sherbourne; R A Olshen; K B Wells; L A Lenert
Journal: Health Serv Res Date: 1998-10 Impact factor: 3.402

Review 10. The person-trade-off approach to valuing health care programs.

Authors: E Nord
Journal: Med Decis Making Date: 1995 Jul-Sep Impact factor: 2.583

30 in total

1. Towards more consistent use of generic quality-of-life instruments.

Authors: Mattias Neyt
Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981

2. The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations.

Authors: Sinaa A Al Aqeel; Mohammed Al-Sultan
Journal: Saudi Pharm J Date: 2011-12-24 Impact factor: 4.330

3. NICE Methodology for Technology Appraisals: cutting edge or tried and trusted?

Authors: Louise Longworth; Carole Longson
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

4. NICE's 2008 Methods Guide: sensible consolidation or opportunities missed?

Authors: Mark Sculpher
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

5. NICE Guide to the Methods of Technology Appraisal: pharmaceutical industry perspective.

Authors: Julia Earnshaw; Gavin Lewis
Journal: Pharmacoeconomics Date: 2008 Impact factor: 4.981

6. Measuring quality of life for certain events versus pre-specified points in time.

Authors: Mattias Neyt
Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981

Review 7. A systematic review and critical assessment of health state utilities: weight change and type 2 diabetes mellitus.

Authors: Scott Doyle; Andrew Lloyd; Lee Moore; Joshua Ray; Alastair Gray
Journal: Pharmacoeconomics Date: 2012-12-01 Impact factor: 4.981

8. Association between knee symptoms, change in knee symptoms over 6-9 years, and SF-6D health state utility among middle-aged Australians.

Authors: Ambrish Singh; Julie A Campbell; Alison Venn; Graeme Jones; Leigh Blizzard; Andrew J Palmer; Terence Dwyer; Flavia Cicuttini; Changhai Ding; Benny Antony
Journal: Qual Life Res Date: 2021-05-03 Impact factor: 4.147

9. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.

Authors: Mark J Harrison; Mark Lunt; Suzanne M M Verstappen; Kath D Watson; Nick J Bansback; Deborah P M Symmons
Journal: Health Qual Life Outcomes Date: 2010-02-11 Impact factor: 3.186

10. Evaluating the consequences of rheumatoid arthritis.

Authors: Björn Sossong; Stefan Felder; Malte Wolff; Klaus Krüger
Journal: Eur J Health Econ Date: 2016-07-28